title: SC-46275: a potent and highly selective agonist at the EP3 receptor.
abstract: The agonist properties of SC-46275 have been investigated in EP receptor subtype-specific smooth muscle assays. In the isolated guinea pig vas deferens (GPVD), prostaglandin E2 (PGE2), via the EP3 receptor, potently inhibited electrically induced contractions with an EC50 of 5.4 +/- 1.1 nM. Sulprostone and misoprostol were both potent relaxers of the GPVD yielding EC50s of 1.6 +/- 0.4 nM and 4.3 +/- 0.9 nM, respectively, while butaprost (10,000 nM) was inactive. SC-46275 was by far the most potent agonist in the GPVD exhibiting an EC50 of 0.04 +/- 0.02 nM. PGE2, via the EP1 receptor, stimulates contractions in the longitudinal muscle layer of the guinea pig ileum (GPIL) with an EC50 of 74.4 +/- 10.6 nM. SC-46275 was extremely weak in this preparation, generating only 33% of the maximal PGE2 effect at 30,000 nM. The circular muscle layer of guinea pig ileum (GPIC) is responsive to inhibition of electrically stimulated contractions by PGE2 (EC50 = 179.6 +/- 20.8 nM) via the EP2 receptor. SC-46275 (up to 10,000 nM) was completely inactive in this preparation. We conclude from these findings that SC-46275 is a very potent and highly selective EP3 receptor agonist. SC-46275 should prove to be an extremely valuable tool in probing the physiological significance of EP3 receptors. The high potency of SC-46275 at the EP3 receptor may account for its antisecretory and cytoprotective actions, while its lack of activity at the EP1 or EP2 sites may explain its very weak diarrheagenic potential.
authors.affiliation: Neurological Diseases Research, Searle Research and Development, Skokie, IL 60077.
authors.forename: M A
authors.initials: MA
authors.lastname: Savage
authors.forename: C
authors.initials: C
authors.lastname: Moummi
authors.forename: P J
authors.initials: PJ
authors.lastname: Karabatsos
authors.forename: T H
authors.initials: TH
authors.lastname: Lanthorn
mesh_terms: D000527:Alprostadil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000897:Anti-Ulcer Agents / Q000494:pharmacology; D015232:Dinoprostone / Q000031:analogs & derivatives / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004558:Electric Stimulation; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects / Q000502:physiology; D066298:In Vitro Techniques; D008297:Male; D016595:Misoprostol / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology; D018078:Receptors, Prostaglandin E / Q000145:classification / Q000187:drug effects* / Q000502:physiology
chemical_list: D000897:Anti-Ulcer Agents; D011459:Prostaglandins E, Synthetic; D018078:Receptors, Prostaglandin E; D016595:Misoprostol; C072122:SC-46275; C016767:sulprostone; D000527:Alprostadil; C048491:butaprost; D015232:Dinoprostone